The Akero Therapeutics Inc Rollercoaster: What’s Behind the Latest AKRO Stock Fluctuation?
Akero Therapeutics Inc (AKRO) stock saw a modest uptick, ending the day at $54 which represents a slight increase of $2.53 or 4.92% from the prior close of $51.47. The stock opened at $52.48 and touched a low of $51.
Bank of America upgraded Akero Therapeutics (NASDAQ:AKRO) on Thursday, citing what it called “game-changing” data the company ...
Why have drugs to treat the liver disease MASH reached a tipping point? How did Hims & Hers convince Childish Gambino to ...
BofA analyst Jason Zemansky upgraded Akero Therapeutics (AKRO) to Buy from Neutral with a $63 price target Invest with Confidence: Follow ...
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) traded up 4.8% during mid-day trading on Wednesday after Morgan ...
Zacks.com on MSN2d
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH StudyAkero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...
It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...
Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...
Akero Therapeutics (NASDAQ:AKRO – Get Free Report) had its target price raised by HC Wainwright from $50.00 to $72.00 in a ...
J.P. Morgan, Morgan Stanley, and Jefferies are acting as joint book-running managers for the offering. UBS Investment Bank is acting as co-manager for the offering.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback